Madrigal Pharmaceuticals, Inc. (MDGL)
538.90
+5.14
(+0.96%)
USD |
NASDAQ |
Aug 31, 16:00
538.90
0.00 (0.00%)
After-Hours: 20:00
Madrigal Pharmaceuticals Cash from Investing (Quarterly) : 34.20M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 34.20M |
| March 31, 2026 | 192.19M |
| December 31, 2025 | 27.58M |
| September 30, 2025 | -207.00M |
| June 30, 2025 | 47.86M |
| March 31, 2025 | 163.88M |
| December 31, 2024 | -47.95M |
| September 30, 2024 | -202.39M |
| June 30, 2024 | -122.10M |
| March 31, 2024 | 98.05M |
| December 31, 2023 | -362.12M |
| September 30, 2023 | 50.20M |
| June 30, 2023 | -3.732M |
| March 31, 2023 | -186.86M |
| December 31, 2022 | 66.39M |
| September 30, 2022 | 65.14M |
| June 30, 2022 | 19.24M |
| March 31, 2022 | 55.93M |
| December 31, 2021 | 15.64M |
| September 30, 2021 | 40.09M |
| June 30, 2021 | -27.32M |
| March 31, 2021 | -33.46M |
| December 31, 2020 | -4.798M |
| September 30, 2020 | 94.75M |
| June 30, 2020 | 19.36M |
| Date | Value |
|---|---|
| March 31, 2020 | 50.46M |
| December 31, 2019 | -30.51M |
| September 30, 2019 | 28.27M |
| June 30, 2019 | 36.44M |
| March 31, 2019 | -3.491M |
| December 31, 2018 | 24.99M |
| September 30, 2018 | -222.03M |
| June 30, 2018 | -80.91M |
| March 31, 2018 | -102.12M |
| December 31, 2017 | 6.085M |
| September 30, 2017 | -16.89M |
| June 30, 2017 | -0.647M |
| March 31, 2017 | -10.56M |
| December 31, 2016 | 10.08M |
| September 30, 2016 | 11.91M |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 14.70M |
| June 30, 2015 | -23.02M |
| March 31, 2015 | 8.317M |
| December 31, 2014 | -0.93M |
| September 30, 2014 | -35.58M |
| June 30, 2014 | 11.48M |
| March 31, 2014 | 16.20M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Exelixis, Inc. | 91.43M |
| Karyopharm Therapeutics, Inc. | -10.04M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 23.33M |
| Cash from Financing (Quarterly) | 3.112M |
| Free Cash Flow | -209.28M |
| Free Cash Flow Per Share (Quarterly) | 0.6545 |
| Free Cash Flow to Equity (Quarterly) | 18.64M |
| Free Cash Flow to Firm (Quarterly) | 27.02M |
| Free Cash Flow Yield | -1.50% |